Induction with anti-T-lymphocyte globulins and human immunoglobulins: A strategy for hyperimmunized liver transplant patients

Table 5 Clinical outcomes, n (%)/mean ± SD

	High-risk group (n = 46)	Low-risk group (n = 46)	P value
Follow up period (months)	35.8 ± 26.1	49.8 ± 25	0.01
ICU stay (days)	10.9 ± 9.9	7.2 ± 5.8	0.04
Re-transplantation	3 (6.5)	2 (4.3)	0.65
Overall mortality rate	11 (23.9)	5 (10.9)	0.09
Cause of death			0.07
HCC recurrence	3 (27.3)	1 (20.0)
Sepsis & multi organ failure	3 (27.3)	2 (40.0)
Cardiovascular events	5 (45.4)	0 (0.0)
Metastatic cancer	0 (0.0)	2 (40.0)
1-year post-transplant complications
Primary nonfunction graft	1 (2.2)	2 (4.5)	0.53
Small for size	2 (4.3)	0 (0.0)	0.16
Hepatic artery stenosis	3 (6.5)	1 (2.3)	0.33
Intestinal obstruction	2 (4.3)	0 (0.0)	0.16
Pancreatic fistula	1 (2.2)	0 (0.0)	0.33
Colonic perforation	1 (2.2)	0 (0.0)	0.33
Hematoma	2 (4.3)	3 (6.8)	0.61
Biliary stenosis	2 (4.3)	2 (4.5)	0.96
CMV reactivation	3 (6.5)	2 (4.5)	0.68
Viral infection	1 (2.2)	0 (0.0)	0.33
Bacterial infection	4 (8.7)	5 (11.4)	0.321
Fungal infection	4 (8.7)	1 (2.3)	0.18
Epilepsy	1 (2.2)	1 (2.3)	0.98
Hypertension	1 (2.2)	0 (0.0)	0.33
Acute kidney injury	8 (17.4)	2 (4.5)	0.05

High SD is due to presence of outliers. CMV: Cytomegalovirus; HCC: Hepatocellular carcinoma; ICU: Intensive care unit.